Thera-SAbDab

BIFIKAFUSP

>   Structural Summary
TherapeuticBifikafusp
TargetFN extra domain B
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb Fusion
IsotypeE
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedPhilogen
Conditions Approvedna
Conditions ActiveCancers, Pancreatic cancer, Metastatic melanoma
Conditions DiscontinuedBrain cancer, Non-small cell lung cancer, Solid tumours
NotesRadretumab+Bifikafusp+Onfekafusp have identical V domains

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]